DRUG ENFORCEMENT ADMINISTRATION related term(s) Department of Justice

Amendments

Drugs: clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), H5212, H5215, H5216, H5217, H5218 [15JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (H. Res. 934), H5113 [13JN]

Articles and editorials

Secret Story of How America Lost the Drug War With the Taliban (excerpt), H6107 [11JY]

Bills and resolutions

Dept. of HHS: develop national milestones to measure success in curtailing the opioid epidemic (see S. 2931), S2877 [23MY]

Dept. of Homeland Security: establish a narcotic drug screening technology pilot program to combat illicit opioid importation (see S. 3047), S3601 [11JN]

Dept. of Justice: prohibit use of amounts from Asset Forfeiture Fund for DEA Domestic Cannabis Suppression/Eradication Program (see H.R. 4816), H477 [17JA]

——— provide grants for drug disposal sites (see H.R. 5557), H3441 [18AP]

——— require registration of tableting or encapsulating machines to assist law enforcement in identifying counterfeit pill makers (see S. 3281), S5423 [26JY] (see H.R. 6554), H7721 [26JY]

Drugs: allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (see S. 2659, 2661), S2120 [12AP]

——— amend certain regulations so that practitioners may not administer more than 3 days’ medication to a person at one time when administering narcotics in order to relieve acute withdrawal symptoms (see H.R. 5770), H3929 [10MY]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (see H. Res. 934), H5092 [12JN]

——— clarify process for denying, revoking, or suspending a registration to manufacture, distribute, or dispense a controlled substance (see H.R. 5267), H1542 [13MR]

——— decriminalize marijuana, use tax revenues to assist certain small businesses, research effects on driving and health, restrict advertising to protect children, and expunge certain marijuana-related convictions (see S. 3174), S4734 [28JN]

——— deem drugs or other substances that act as opioid mu receptor antagonists to be in Schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 5298), H1651 [15MR]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse (see S. 2535), S1629 [12MR]

——— establish a national clearinghouse for all orders of controlled substances and require such orders pass through a database to identify suspicious orders and notify suppliers before orders are filled (see S. 3282), S5423 [26JY] (see H.R. 6600), H7723 [26JY]

——— improve medical research on marijuana (see H.R. 4825), H552 [18JA]

——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment (see S. 2711), S2321 [19AP]

——— improve oversight of new opioids and education of prescribers, limit availability of addictive painkillers, strengthen prescription drug monitoring, and establish drug disposal programs (see S. 2729), S2342 [23AP] (see H.R. 5865), H4209 [17MY]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues (see H.R. 6047), H4980 [7JN]

——— improve systems for identifying diversion of controlled substances (see S. 2837), S2643 [14MY]

——— include fentanyl analogues under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 4922), H782 [5FE]

——— increase penalties for fentanyl trafficking (see S. 2481), S1316 [1MR] (see H.R. 6057), H5020 [8JN]

——— modify offenses relative to fentanyl (see S. 2635), S2012 [9AP] (see H.R. 5459), H3095 [10AP]

——— prevent substance abuse and reduce demand for illicit narcotics (see S. 2789), S2485 [26AP] (see H.R. 5933), H4692 [23MY]

——— provide for delivery of a controlled substance by a pharmacy to an administering practitioner (see H.R. 5202), H1476 [7MR]

——— regulate selective androgen receptor modulators in the same manner as anabolic steroids (see S. 2742), S2391 [24AP]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (see S. 2838), S2678 [15MY] (see H.R. 6491), H7154 [24JY] (see H.R. 6779), H8169 [12SE]

——— restore ability to target pharmaceutical companies distributing opioids in certain communities by implementing a probable cause standard for intervention and striking the corrective action plan option (see S. 2493), S1338 [5MR] (see H.R. 6702), H7870 [5SE]

——— strengthen penalties on drug companies that fail to monitor and report suspicious opioid distribution practices and increase transparency of Federal oversight of opioid manufacturing and advertising (see S. 2440), S1164 [15FE]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (see S. 2561), S1765 [15MR]

FDA: hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (see S. 2691), S2218 [17AP] (see H.R. 5782), H3935 [11MY]

Federal employees: commemorate anniversary, honor employees killed or injured in service, and thank all past and present employees (see S. Res. 578), S5066 [18JY]

Health care facilities: allow certain community mental health centers to register as a clinic to allow telemedicine providers to prescribe controlled substances (see H.R. 5594), H3505 [24AP]

Information technology: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (see H.R. 5483), H3209 [12AP]

Internet: make publicly available online a report on the sale of controlled substances and controlled substance analogues over the Internet (see H.R. 5021), H1177 [14FE]

Languages: provide a cash award to employees with foreign language skills (see H.R. 6210), H5648 [25JN]

Science, Depts. of Justice and Commerce, and related agencies: making appropriations (see S. 3072), S3951 [14JN] (see H.R. 5952), H4728 [24MY]

States: provide grants to certain States to increase participation in drug take-back programs (see S. 2645), S2075 [11AP] (see H.R. 5628), H3705 [26AP]

U.S. Intelligence Professionals Day: designate (see S. Res. 595), S5424 [26JY]

Letters

Opioid drug abuse prevention legislation: Representative Kevin Brady, Committee on Ways and Means (House), H5033, H5062, H5065 [12JN], H5238, H5241, H5248, H5257, H5260, H5262, H5264 [19JN]

——— Representative Walden, Committee on Energy and Commerce (House), H5033, H5062, H5065 [12JN], H5237, H5241, H5248, H5258, H5260, H5262, H5264 [19JN]

Remarks in House

Chatham County, GA: tribute to Chatham-Savannah Counter Narcotics Team, H3729 [27AP]

Dept. of Justice: establish a national pharmaceutical stewardship program to facilitate collection and disposal of prescription medications (H.R. 4199), H3825 [8MY]

Drugs: address prescription opioid and heroin abuse, H7692 [26JY]

——— authorize evidence based report analyzing current marijuana policies and their effects on communities, H6637 [23JY]

——— clarify definition of ‘‘imminent danger to the public health or safety’’ to restore authority to suspend a pharmaceutical distributor’s license under certain circumstances (H.R. 4079), E888 [21JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), H5001 [8JN], H5099 [13JN], H5204–H5221 [15JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (H. Res. 934), H5107–H5115 [13JN], E841 [14JN]

——— define what constitutes a controlled substance analogue, clarify temporary import and distribution controls of certain synthetic drugs, and ensure Federal researchers can continue controlled substance research, H5215, H5216 [15JN]

——— improve ability to address synthetic opioid epidemic (H.R. 1781), H544 [18JA]

——— making appropriations to address heroin and opioid drug abuse epidemic, H607 [21JA]

——— report on the sale of lawful and unlawful controlled substance analogues over the Internet, H5218 [15JN]

——— specify the factors used to determine whether a controlled substance analogue is intended for human consumption, H5218–H5220 [15JN]

FDA: hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (S. 2691), H3588 [26AP]

Information technology: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment, H9248 [28SE]

——— allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (H.R. 5483), H5060, H5061 [12JN], E1537 [16NO]

National Prescription Drug Take-Back Day: observance, H3689, H3690, H3691 [26AP]

Obama, Barack: allegations of interference in DEA investigation into drug trafficking and money laundering by Hezbollah (terrorist organization) in order to secure agreement relative to Iran’s nuclear program, H68, H69 [9JA]

——— evaluation of administration relative to drug trafficking policies, H6107 [11JY]

Pharmacists: develop training materials covering circumstances when a pharmacist may decline to fill a prescription due to suspicion the prescription is fraudulent, forged, or indicative of abuse (H.R. 4275), H5066, H5067 [12JN]

Remarks in Senate

Dept. of HHS: develop national milestones to measure success in curtailing the opioid epidemic, S6162 [17SE], S6463 [3OC]

Drugs: address prescription opioid and heroin abuse, S5049 [18JY], S5101–S5103 [19JY], S5326 [25JY], S5603–S5606 [15AU], S5746–S5748 [21AU], S6209 [18SE], S6796 [11OC], S7175–S7178 [28NO]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals, S6472 [3OC]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (S. 2659), S2105 [12AP]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse, S6174 [17SE]

——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment, S6164 [17SE]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues, S6473 [3OC]

——— making appropriations to address heroin and opioid drug abuse epidemic, S146–S148 [11JA], S280 [18JA], S321 [19JA], S629 [6FE], S812–S815 [8FE], S887 [12FE]

——— prevent substance abuse and reduce demand for illicit narcotics, S6120 [12SE]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders, S6471 [3OC]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (S. 2838), S2680 [15MY], S3596 [11JN]

——— strengthen penalties on drug companies that fail to monitor and report suspicious opioid distribution practices and increase transparency of Federal oversight of opioid manufacturing and advertising, S3596 [11JN], S6173 [17SE]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (S. 2561), S1766 [15MR]

Federal employees: commemorate anniversary, honor employees killed or injured in service, and thank all past and present employees (S. Res. 578), S5312 [24JY]

Law enforcement: address importation of illegal drugs, S4388 [26JN]

National Prescription Drug Take-Back Day: observance, S2464 [26AP]

Obama, Barack: allegations of interference in DEA investigation into drug trafficking and money laundering by Hezbollah (terrorist organization) in order to secure agreement relative to Iran’s nuclear program, S16 [3JA]

Science, Depts. of Justice and Commerce, and related agencies: making appropriations, S7382 [10DE]

——— making appropriations (S. 3072), S6203–S6205 [18SE]

U.S. Intelligence Professionals Day: designate (S. Res. 595), S5437, S5438 [26JY]

Reports filed

Access to Increased Drug Disposal Act: Committee on the Judiciary (Senate) (S. 2645), S4035 [19JN]

Consideration of H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act: Committee on Rules (House) (H. Res. 934) (H. Rept. 115–751), H5092 [12JN]

Opioid Quota Reform Act: Committee on the Judiciary (Senate) (S. 2535), S4035 [19JN]

Opportunities To Provide for Illicit Opioid Interdiction and Detection (OPIOID) Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 3047) (S. Rept. 115–353), S6924 [13NO]

Preventing Drug Diversion Act: Committee on the Judiciary (Senate) (S. 2837), S4035 [19JN]

Science, Depts. of Justice and Commerce, and Related Agencies Appropriations: Committee on Appropriations (House) (H.R. 5952) (H. Rept. 115–704), H4728 [24MY]

——— Committee on Appropriations (Senate) (S. 3072) (S. Rept. 115–275), S3951 [14JN]

Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act: Committee on the Judiciary (House) (H.R. 2851) (H. Rept. 115–713), H5020 [8JN]

Substance Abuse Prevention Act: Committee on the Judiciary (Senate) (S. 2789), S4035 [19JN]

Synthetic Abuse and Labeling of Toxic Substances (SALTS) Act: Committee on the Judiciary (Senate) (S. 207), S4035 [19JN]

Using Data To Prevent Opioid Diversion Act: Committee on the Judiciary (Senate) (S. 2838), S4035 [19JN]

Texts of

H. Res. 934, consideration of H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act, H5107 [13JN]

H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act, H5212–H5215 [15JN]

H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act, H5066 [12JN]

H.R. 5483, Special Registration for Telemedicine Clarification Act, H5060 [12JN]

S. 2535, Opioid Quota Reform Act, S1632 [12MR]

S. 2729, Addiction Prevention and Responsible Opioid Practices Act, S2343–S2346 [23AP]

S. 2789, Substance Abuse Prevention Act, S2487–S2490 [26AP]

S. 3174, Marijuana Freedom and Opportunity Act, S4740 [28JN]

S. Res. 578, commemorate DEA anniversary, honor employees killed or injured in service, and thank all past and present employees, S5070 [18JY]

S. Res. 595, U.S. Intelligence Professionals Day, S5428 [26JY]